Analysts Offer Insights on Healthcare Companies: Ceribell, Inc. (CBLL) and AbCellera Biologics (ABCL)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ceribell, Inc. (CBLL) and AbCellera Biologics (ABCL) with bullish sentiments.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ceribell, Inc. (CBLL)
TD Cowen analyst Josh Jennings maintained a Buy rating on Ceribell, Inc. today and set a price target of $29.00. The company’s shares closed last Monday at $20.06, close to its 52-week low of $18.69.
According to TipRanks.com, Jennings is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ceribell, Inc. with a $29.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
AbCellera Biologics (ABCL)
TD Cowen analyst Brendan Smith maintained a Buy rating on AbCellera Biologics yesterday. The company’s shares closed last Monday at $5.25.
According to TipRanks.com, Smith is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for AbCellera Biologics with a $8.00 average price target, representing a 46.1% upside. In a report issued on May 5, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $7.00 price target.
Read More on CBLL:
Disclaimer & DisclosureReport an Issue
- Ceribell’s Earnings Call Signals Growth Over Profits
- Ceribell reports Q1 EPS (52c), consensus (39c)
- Ceribell sees FY26 revenue $112M-$116M, consensus $113.18M
- Ceribell Targets ICU Delirium With New EEG Study, Signaling Wider Market Ambitions
- Ceribell receives 510(k) premarket notification for brain monitor headband
